Endonovo Therapeutics (ENDV) Total Non-Current Liabilities (2016 - 2023)
Endonovo Therapeutics has reported Total Non-Current Liabilities over the past 8 years, most recently at $17.9 million for Q3 2023.
- Quarterly results put Total Non-Current Liabilities at $17.9 million for Q3 2023, down 14.8% from a year ago — trailing twelve months through Sep 2023 was $17.9 million (down 14.8% YoY), and the annual figure for FY2022 was $33.4 million, up 88.58%.
- Total Non-Current Liabilities for Q3 2023 was $17.9 million at Endonovo Therapeutics, down from $23.1 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ENDV hit a ceiling of $33.4 million in Q4 2022 and a floor of $11.0 million in Q1 2020.
- Median Total Non-Current Liabilities over the past 5 years was $13.9 million (2021), compared with a mean of $15.9 million.
- Biggest five-year swings in Total Non-Current Liabilities: soared 88.58% in 2022 and later dropped 14.8% in 2023.
- Endonovo Therapeutics' Total Non-Current Liabilities stood at $13.2 million in 2019, then grew by 27.67% to $16.8 million in 2020, then increased by 5.21% to $17.7 million in 2021, then skyrocketed by 88.58% to $33.4 million in 2022, then tumbled by 46.46% to $17.9 million in 2023.
- The last three reported values for Total Non-Current Liabilities were $17.9 million (Q3 2023), $23.1 million (Q2 2023), and $16.2 million (Q1 2023) per Business Quant data.